Trial · NCT04875975
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Seizure Free Study Participants at the End of the Treatment | Placebo | 1 | Participants | ||
| Number of Seizure Free Study Participants at the End of the Treatment | Rozanolixizumab (RLZ) | 0 | Participants | ||
| Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at the End of the Treatment | Placebo | Week 5 | 4.5 | Standard Deviation 2.6 | score on a scale |
| Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at the End of the Treatment | Rozanolixizumab (RLZ) | Week 5 | 2.2 | Standard Deviation 11.3 | score on a scale |
| Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at the End of the Treatment | Placebo | Week 13 | 7.0 | Standard Deviation 2.9 | score on a scale |
| Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at the End of the Treatment | Rozanolixizumab (RLZ) | Week 13 | 12.3 | Standard Deviation 7.9 | score on a scale |
| Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at the End of the Treatment | Placebo | Week 21 | 7.0 | Standard Deviation 7.3 | score on a scale |
| Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at the End of the Treatment | Rozanolixizumab (RLZ) | Week 21 | NA | Standard Deviation NA | score on a scale |
| Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at the End of the Treatment | Placebo | Week 25 | NA | Standard Deviation NA | score on a scale |
| Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at the End of the Treatment | Rozanolixizumab (RLZ) | Week 25 | NA | Standard Deviation NA | score on a scale |
| Percentage of Participants With a Favorable Outcome in the Modified Rankin Scale (mRS) During the Treatment | Placebo | NA | percentage of participants | ||
| Percentage of Participants With a Favorable Outcome in the Modified Rankin Scale (mRS) During the Treatment | Rozanolixizumab (RLZ) | NA | percentage of participants | ||
| Number of Participants Who Required Rescue Medication Due to an Absence or Loss of Clinical Benefit During the Treatment | Placebo | 3 | Participants | ||
| Number of Participants Who Required Rescue Medication Due to an Absence or Loss of Clinical Benefit During the Treatment | Rozanolixizumab (RLZ) | 2 | Participants | ||
| Time to First Occurrence of Seizure Freedom During the Treatment | Placebo | 0.1 | Full Range 0.1 to 8.4 | Weeks | |
| Time to First Occurrence of Seizure Freedom During the Treatment | Rozanolixizumab (RLZ) | 0.1 | Full Range 0.1 to 8.3 | Weeks | |
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) | Placebo | 100 | percentage of participants | ||
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) | Rozanolixizumab (RLZ) | 100 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04875975/results